No Data
Individual Investors Who Own 46% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Humacyte Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $17
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)
Express News | Humacyte Inc : Benchmark Raises Target Price to $17 From $15